Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

ild to moderate, regardless of causality) occurred in 10.3% of patients receiving PREZISTA/ritonavir. Discontinuation due to rash was 0.5%


  • Sulfa Allergy: PREZISTA should be used with caution in patients with known sulfonamide allergy

  • Diabetes Mellitus/Hyperglycemia and Hemophilia: New-onset or exacerbations of preexisting diabetes mellitus, hyperglycemia, and increased bleeding in hemophiliacs have been reported in patients receiving protease inhibitors. Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. A causal relationship between protease inhibitors and these events has not been established

  • Fat Redistribution: Redistribution and/or accumulation of body fat have been observed in patients receiving ARV therapy. The causal relationship, mechanism, and long-term consequences of these events have not been established

  • Immune reconstitution syndrome has been reported in patients treated with ARV therapy

  • Resistance/Cross Resistance: The potential for HIV-1 cross-resistance among protease inhibitors has not been fully explored in PREZISTA/ritonavir-treated patients

  • Use in Specific Populations

  • Hepatic Impairment: PREZISTA/ritonavir is not recommended for use in patients with severe hepatic impairment. There are no pharmacokinetic or safety data available in patients with severe hepatic impairment

  • Pregnancy: PREZISTA should be used during pregnancy only if the potential benefit justifies the potential risk. No adequate and well-controlled studies have been conducted in pregnant women

  • Adverse Reactions

  • In treatment-naïve adult patients, the most common adverse drug reactions (greater than or equal to 5%) reported of at least
    '/>"/>

  • SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
    (Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
    (Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
    ... Jan. 19, 2011 RFID Journal features ... Someone can live or die depending on the ... agree leveraging better tracking of a drug,s expiration dates, ... levels, all performed in REAL TIME, would assist in ...
    ... PRINCETON, N.J., Jan. 18, 2011 Pharmasset, Inc. (Nasdaq: ... commenced an underwritten public offering, subject to market and ... pursuant to an effective shelf registration statement.  Of the ... the selling stockholders are selling 1,000,000 shares.  Pharmasset intends ...
    Cached Medicine Technology:MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2Pharmasset Announces Proposed Public Offering of Common Stock 2Pharmasset Announces Proposed Public Offering of Common Stock 3
    (Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted living ... p.m. to 4 p.m. on Feb. 13. , The community, which ... with physical disabilities between the ages of 22 and 64. , ... sweetheart-themed karaoke. , For more information about the event or Deer ...
    (Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
    (Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
    (Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
    (Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
    Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
    ... /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the ... final results of its separate concurrent fixed price exchange offers ... any and all of the approximately $118.9 million outstanding principal ... The Exchange Offers expired at 5:00 p.m., New York ...
    ... As President Obama prepares to sign a bill giving ... tobacco industry, a new study from Harvard School of ... continually changed the ingredients and the design of their ... acceptable product variance guidelines. The result, say the researchers, ...
    ... The Damon Runyon Cancer Research Foundation, a non-profit ... and innovative cancer research, named 17 new Damon ... Committee review. The recipients of this prestigious, three-year ... translational cancer research in the laboratories of leading ...
    ... in Williamson County ... Round Rock Medical Center today announced that the hospital will seek ... Williamson County. , , "St. David,s Round Rock Medical Center ... has the busiest emergency department in the City of Round Rock ...
    ... their choice , FRIDAY, June 19 (HealthDay News) -- ... can,t list any actual benefits, a new British study ... BMC Public Health , stemmed from interviews that University ... sports center. , "The majority of participants believed that ...
    ... WLP ) will release second quarter 2009 financial results on July 29, ... and its outlook during a conference call at 8:30 a.m. EDT that same ... its start with the following numbers: , , , ... 800-475-6701 (Domestic Replay), ...
    Cached Medicine News:Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 4Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 5Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 2Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 3Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 4Health News:WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29, 2009 2